14 hours ago
1
Rasi Bhadramani/iStock via Getty Images
The U.S. FDA said on Monday that it recommends lifting the voluntary hold on Sarepta Therapuetics' gene therapy, Elevidys, in ambulatory patients.
Last Friday, the FDA said that it will investigate the death of an 8-year-old boy who received Elevidys, a treatment
© FBT Company 2025. All rights are reserved
English (US) ·